SVR24 rates in patients with HCV genotype 5 and 6 infection treated with peginterferon alfa-2a (40KD) plus ribavirin: results from the real world PROPHESYS study

Ann Hepatol. 2014 Mar-Apr;13(2):303-4.
No abstract available

Publication types

  • Letter
  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antiviral Agents / therapeutic use
  • Cohort Studies
  • Dose-Response Relationship, Drug
  • Drug Therapy, Combination
  • Female
  • Genotype*
  • Hepacivirus / genetics*
  • Hepatitis C / blood
  • Hepatitis C / drug therapy*
  • Humans
  • Interferon-alpha / therapeutic use*
  • International Cooperation
  • Male
  • Middle Aged
  • Polyethylene Glycols / therapeutic use*
  • Pragmatic Clinical Trials as Topic
  • RNA, Viral / blood*
  • Recombinant Proteins / therapeutic use
  • Ribavirin / therapeutic use*
  • Treatment Outcome
  • Viral Load*

Substances

  • Antiviral Agents
  • Interferon-alpha
  • RNA, Viral
  • Recombinant Proteins
  • Polyethylene Glycols
  • Ribavirin
  • peginterferon alfa-2a